Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01519661 |
|
Recruitment Status :
Completed
First Posted : January 27, 2012
Results First Posted : February 10, 2015
Last Update Posted : February 10, 2015
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary Infections Pseudomonas Aeruginosa in Cystic Fibrosis | Drug: TBM100 | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 157 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis |
| Study Start Date : | January 2012 |
| Actual Primary Completion Date : | January 2014 |
| Actual Study Completion Date : | January 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Cystic fibrosis
MedlinePlus related topics:
Cystic Fibrosis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Tobramycin Inhalation Powder (TIP)
Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
|
Drug: TBM100
Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler. |
Primary Outcome Measures :
- Percentage of Participants With Treatment Emergent Adverse Events, Serious Adverse Events (SAEs) and Deaths [ Time Frame: 337 days ]Adverse events were deemed treatment-emergent if the onset date/time was on or after the date and time of first study drug. All adverse events were included after this time during both on and off-treatment periods.
Secondary Outcome Measures :
- Relative Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Percent Predicted [ Time Frame: Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period. ]Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recorded at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day X FEV1 % predicted - baseline FEV1 % predicted) / baseline FEV1 % predicted) • 100.
- Relative Change From Baseline in FVC Percent Predicted [ Time Frame: Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period. ]Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recorded at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FVC % predicted from baseline to pre-dose day X = ((pre-dose day X FVC % predicted - baseline FVC % predicted) / baseline FVC % predicted) • 100.
- Relative Change From Baseline in FEF Rate Over 25 to 75 Percent of Vital Capacity Predicted [ Time Frame: Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337. All study visits except baseline and day 337 occurred at the end of a 28-day on-treatment period of a cycle. Day 337 was the end of the final 28-day off treatment period. ]Spirometry was performed at each visit. FEV1, FVC, and FEF25-75 were recored at all visits according to American Thoracic Society (ATS) guidelines. FEV1 = the volume of air expired in 1 second. FEV1 % predicted is a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. FVC (forced vital capacity) = the maximal volume of air exhaled with maximally forced effort from a position of maximal inspiration. FEF25-75 = forced expiratory flow from 25% to 75% of the FVC. Relative change in FEEF25-75 from baseline to pre-dose day X = ((pre-dose day X FEF25-75 - baseline FEF25-75) / baseline FEF25-75) • 100.
- Change From Baseline in Pseudomonas Aeruginosa Colony Forming Units in Sputum [ Time Frame: Baseline, day 1, day 29, day 85, day 141, day 197, day 253, day 309, day 337 ]Sputum was collected in sterile containers and cultured for Pseudomonas aeruginosa (Pa.) (quantitative test) and other typical Cystic Fibrosis respiratory pathogens. The Pa. biotypes measured were mucoid, dry and small colony variant. Results are presented for the sum of all biotypes of Pa, with data transformed using a base 10 logarithm.
- Tobramycin MIC 50 and MIC 90 Values Over All Isolates for the Sum of All Biotypes (Mucoid, Dry and Small Colony Variant) of Pseudomonas Aeruginosa [ Time Frame: Baseline, day 29, day 85, day 141, day 197, day 253, day 309, day 337 ]Tobramycin MIC 50 and MIC 90 values were defined as the lowest concentration of tobramycin required to inhibit 50% and 90%, respectively, of the P. aeruginosa strains tested.
- Percentage of Participants Hospitalized Due to Serious Respiratory-related Adverse Events [ Time Frame: Day 337 ]
- Number of Hospitalization Days Due to Serious Respiratory-related Adverse Events [ Time Frame: Day 337 ]The total number of hospitalization days due to serious respiratory-related adverse events was analyzed.
- Time to First Hospitalization Due to Serious Respiratory-related Adverse Events [ Time Frame: Day 337 ]The day of first hospitalization due to serious respiratory-related adverse events was analyzed.
- Percentage of Participants Who Used New Anti-pseudomonal Antibiotics [ Time Frame: Day 337 ]
- Number of Days of New Anti-pseudomonal Antibiotic Use [ Time Frame: Day 337 ]The total number of days of new anti-pseudomonal antibiotic use was analyzed.
- Time to Use of New Anti-pseudomonal Antibiotic [ Time Frame: Day 337 ]Time to first use of new anti-pseudomonal antibiotic was analyzed.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Confirmed diagnosis of Cystic Fibrosis
- FEV1 at screening must be between 25 and 75 percent of normal predicted values for age, sex and height based on the Knudson equation
- Pseudomonas aeruginosa must be present in a sputum / deep cough throat swab culture or bronchoalveolar lavage within 6 months prior to screening and in the sputum/deep-throat cough swab culture at screening
Exclusion Criteria:
- History of sputum culture or deep cough throat swab culture yielding Burkholderia cenocepacia complex within 2 years prior to screening and /or sputum culture yielding Burkholderia cenocepacia at screening
- Hemoptysis more than 60mL at any time within 30 days prior to study drug administration
- History of hearing loss or chronic tinnitus deemed clinically significant
- Serum creatinine 2mg/dl or more, BUN 40mg/dl or more, or an abnormal urinalysis defined as 2+ or greater proteinuria at screening
- Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics
- Patients who are regularly receiving more than 1 class of inhaled anti-pseudomonal antibiotic
- Any use of inhaled or systemic anti-pseudomonal antibiotic within 28 days prior to study drug administration
- Use of loop diuretics within 7 days prior to study drug administration
Other protocol-defined inclusion/exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01519661
Locations
Show 49 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01519661 |
| Other Study ID Numbers: |
CTBM100C2401 2011-002000-32 ( EudraCT Number ) |
| First Posted: | January 27, 2012 Key Record Dates |
| Results First Posted: | February 10, 2015 |
| Last Update Posted: | February 10, 2015 |
| Last Verified: | February 2015 |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
Tobramycin Inhalation powder Cystic fibrosis Lung disease Anti-bacterial agents |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Respiratory Aspiration Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Respiration Disorders |